Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and may limit disease progression and complications.

Matéria original

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing￼

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing